Combination drug whose action is due to its constituent components: the antidepressant masteron prop and anxiolytic chlordiazepoxide. It has a pronounced anti-depressant and anxiolytic effects.
The mechanism of action is based on masteron prop inhibition of reuptake of norepinephrine and serotonin. in the CNS; chlordiazepoxide – is determined by the stimulation of benzodiazepine receptors supramolecular GABA-benzodiazepine-hlorionofor prescription complex, resulting in the activation of GABA receptor, causes a decrease in the excitability of the subcortical structures of the brain, spinal reflexes polysynaptic braking.
Orally reception Amiksida maximum plasma concentrations are attained within 4-8 hours. (Because masteron prop slows down the transit time in the digestive tract, absorption can be slowed down, especially in overdose). masteron prop binds to the plasma protein at 94%; the half-life of about 20h. Chlordiazepoxide bound to plasma proteins by 96%; the half-life of about 10h. Both components are metabolized in the liver. The half-life of the active metabolite of masteron prop (noratriptilina) is 80 hours. The half-life of the active metabolite of chlordiazepoxide (desmethyl-chlordiazepoxide) is 1-4 days.
The drug crosses the placental barrier and is excreted in breast milk.
Apply strictly prescribed by a doctor.
Depression different genesis, the structure of which there is a disturbing syndrome of varying severity.
Acute intoxication from drugs, have a depressing effect on the central nervous system
- Decompensated heart defects.
- Acute and recovery phase of myocardial infarction.
- conduction disorders of the heart muscle.
- Acute liver and kidney disease, with severe dysfunction.
- Hyperthyroidism and simultaneous treatment of thyroid-stimulating drugs.
- Peptic ulcer and 12 duodenal ulcer in the acute stage.
- Angle-closure glaucoma.
- Prostate Hypertrophy.
- Atony of the bladder.
- Pyloric stenosis, paralytic ileus.
- Simultaneous treatment of MAO inhibitors.
- Severe myasthenia gravis.
- Pregnancy, lactation.
- Hypersensitivity to any component of the drug.
Be wary – absence (petit mal) or Lennox-Gastaut syndrome; epilepsy or seizures in history, liver and / or kidney failure, cerebral and spinal ataxia, hyperkinesis, a tendency to abuse of psychotropic drugs, organic brain disease (possible paradoxical reactions), hypoproteinemia, advanced age.
Dosing and Administration
Assign inside (after eating), the dose can be set individually.
The initial daily dose – 12.5 1 tablet / 5mg 2-3 times daily. If necessary, the dose can be increased up to 6 mg 25/10 tablets a day for 2-3 hours.
Upon receipt of proof of antidepressant effect in 2-4 weeks the dose gradually and slowly reduced. In the case of depression symptoms at lower doses need to go back to the previous dose.
If the patient’s condition does not improve within 3-4 weeks of treatment, further treatment is not practical.
In elderly patients with pulmonary disorders in outpatient practice, doses of up to 12.5 / 5 mg; 25/25 or 5mg / 10mg usually 1 time per day at night.
are mainly related to the anticholinergic effect of the drug, paresis of accommodation, blurred vision, increased intraocular pressure, dry mouth, constipation, ileus, urinary retention, increase in body temperature. These effects usually disappear after adaptation to the drug or dose reduction.
CNS: headache, ataxia, fatigue, weakness, irritability, dizziness, tinnitus, drowsiness or insomnia, impaired concentration, nightmares, dysarthria, confusion, hallucinations, motor agitation, confusion, tremor, paresthesia, peripheral neuropathy, changes in the EEG. Rarely – extrapyramidal disorders, convulsions, anxiety.
Cardio-vascular system: tachycardia, arrhythmias, conduction disturbances, labile blood pressure, expansion of the QRS complex on the ECG (violation of intraventricular conduction), symptoms of heart failure, syncope.
On the part of the digestive tract: nausea, vomiting, heartburn, anorexia, stomatitis, taste disturbances, dark tongue, epigastric discomfort, gastralgia, increased activity of “liver” transaminases. rarely cholestatic jaundice, diarrhea
From endocrine system: an increase in the size of the mammary glands in men and women, galactorrhea, changes in the secretion of antidiuretic hormone (ADH), changes in libido, potency. Rarely – hypo- or hyperglycemia, glycosuria, glucose intolerance, swelling of the testicles.
Allergic reactions: skin rash, pruritus, photosensitivity, angioedema, urticaria.
Other: agranulocytosis, leukopenia, eosinophilia, thrombocytopenia, purpura and other changes in the blood, hair loss, swollen lymph nodes, weight gain during prolonged use, sweating, pollakiuria, muscle weakness.
With prolonged treatment, especially in high doses, the sudden cessation of treatment may develop withdrawal symptoms: headache, nausea, vomiting, diarrhea, and irritability, sleep disturbance with bright, unusual dreams, irritability.
Drowsiness, depression of consciousness of varying degrees of severity up to coma, confusion, dysarthria, psychomotor agitation, hallucinations, numbness, seizures, muscle stiffness, vomiting, arrhythmia, hypotension, heart failure, respiratory depression.
aid measures: Amiksidom cessation of therapy, gastric lavage, infusion fluid, detoxification, the introduction of physostigmine 1-3 mg every 1 / 2-2 hours / m or / in, symptomatic therapy, blood pressure and maintaining water and electrolyte balance. Displaying prolonged observation since recurrence of symptoms of intoxication can occur within 48 hours.
Interaction with other drugs
The drug is advisable to use in monotherapy, as masteron prop and chlordiazepoxide combination in combination with other medications in many cases it may be unpredictable.
Active components included in Amiksid potentiate CNS depression following medicines: antipsychotics, sedatives and hypnotics, anticonvulsants, analgesics, anesthetics, alcohol.
In a joint application Amiksida with neuroleptics, and / or anticholinergic drugs can cause febrile temperature reaction, paralytic ileus.
Active components included in Amiksid potentiate the hypertensive effects of catecholamines, but inhibit the effects of drugs acting on the release of noradrenaline (turamin).
Active components included in Amiksid may block the antihypertensive effect of guanethidine and drugs with a similar mechanism of action.
At simultaneous reception Amiksida and cimetidine may increase the concentration of masteron prop in plasma.
Simultaneous reception Amiksida with MAO inhibitors can be fatal. Break in treatment between the intake of MAO inhibitors and tricyclic antidepressants should not be less than 14 days!
masteron prop in doses above 150 mg / day reduces the threshold for seizure activity, therefore it is necessary to take into account the possibility of seizures in patients with such a history and a category of patients who are predisposed to it due to age or injury.
Amiksin treatment in the elderly should take place under strict control, with minimal doses and gradually increase them, in order to avoid the development of delirium disorders, hypomania, and other complications.
Patients with depressive phase of manic-depressive syndrome can go to the manic phase.
In renal / hepatic failure and prolonged treatment is necessary to monitor the pattern of peripheral blood and “liver” enzymes.
The risk of drug dependence increases when using large doses, a significant duration of treatment in patients who previously abused alcohol or drugs. should not be used long-term without specific instructions.
It is unacceptable abrupt discontinuation of treatment because of the risk of “withdrawal syndrome”
During reception Amiksida prohibited from driving vehicles, machinery maintenance and other work requiring high concentration. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.